Yingtao Lin

9PUBLICATIONS
55CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Mar 03, 2026
Neoadjuvant therapy of iparomlimab and tuvonralimab combined with chemotherapy-extenuated for locally advanced cervical cancer (NICE-CC): an investigator-initiated, multicentre, open-label, phase II trial.

Jie Lin, Qiaoling Wu, Bin Liu

|Nov 26, 2025
Molecular and Immune Correlates of Response to First-Line De-escalated Chemotherapy plus Penpulimab and Anlotinib in Advanced Cervical Cancer.

Qin Xu, Zhengrong Deng, Jing Liu

|Nov 20, 2025
Cost-Effectiveness of First-Line Zuberitamab-CHOP versus Rituximab-CHOP Regimens in Untreated CD20+ Diffuse Large B-Cell Lymphoma in China.

Lihong Gao, Haomin Zhu, Jia Wang

|Oct 06, 2025
Cost-effectiveness analysis of belzutifan versus everolimus for previously treated advanced clear cell renal cell carcinoma in the United States and China.

Baolong Ding, Hongting Yao, Tiantian Tao

|Mar 25, 2025
Cost-effectiveness of PD-1 inhibitors combined with chemotherapy for first-line treatment of oesophageal squamous cell carcinoma in China: a comprehensive analysis.

Kai Xu, Man Yu, Qingli Sun

|May 30, 2024
Economic evaluation of camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma in the United States and China.

Jingxuan Wei, Kai Xu, Yingtao Lin

Pageof 2

Frequent Collaborators

6 joint publications

Xin Li

2 joint publications

Shengtao Zhou

2 joint publications

Yang Sun

1 joint publications

Tian-Xiu Liu